On March 6, 2025, Rigel Pharmaceuticals Inc. (NASDAQ:RIGL), a company specializing in pharmaceutical preparations with a market capitalization of $347 million and impressive revenue growth of 55% ...

Revenue: US$179.3m (up 55% from FY 2023). Net income: US$17.5m (up from US$25.1m loss in FY 2023). Profit margin: 9.8% (up from net loss in FY 2023). The move to profitability was driven by higher ...

SOUTH SAN FRANCISCO - Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL), a biopharmaceutical company showing strong financial health according to InvestingPro metrics, today announced the appointment of ...

(RTTNews) - Rigel Pharmaceuticals Inc. (RIGL) released earnings for its fourth quarter that increased from the same period last year The company's bottom line came in at $14.34 million, or $0.80 ...

These increases were partially offset by decreased research and development costs due to the timing of clinical trial activities related to R289, Rigel's dual IRAK 1/4 inhibitor program ...

Several research firms have recently issued reports on RIGL. B. Riley increased their price objective on shares of Rigel Pharmaceuticals from $17.00 to $27.00 and gave the stock a “neutral ...

Ahead of the iOS 18.4 beta release, Apple watchers were expecting big things for Siri, the personal assistant on the iPhone that's getting a reboot as part of the Apple Intelligence rollout.

On the plus side, the new beta adds more in the realm of Apple Intelligence. You can now enable Priority Notifications, which prompt the built-in AI to show them at ...